Development of liposomal drug delivery system as a strategy for improving bioavailability and therapeutic efficacy, by design of experiments : a case study by Tefas, Lucia Ruxandra et al.
III. Symposium of Young Researchers on Pharmaceutical 
Technology, Biotechnology and Regulatory Science 






Development of liposomal drug delivery system as a 
strategy for improving bioavailability and therapeutic 
efficacy, by Design of Experiments. A case study 
Lucia Ruxandra Tefas1, Cătălina Bogdan2, Alina Porfire1, 
Tryfon Digkas3, Thomas De Beer3, Ioan Tomuță1 
1Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and 
Pharmacy „Iuliu Hațieganu”, Cluj-Napoca, Romania  
2Department of Dermopharmacy and Cosmetics, Faculty of Pharmacy, University of Medicine and Pharmacy 
“Iuliu Hațieganu”, Cluj-Napoca, Romania 
3Laboratory of Pharmaceutical Process Analytical Technology, Department of Pharmaceutical Analysis, Ghent 
University, Ghent, Belgium 
 
There is mounting evidence for the anticancer effects of all-trans retinoic acid (ATRA) in different types 
of malignancies. However, ATRA treatment is usually associated with side effects, and most 
importantly with retinoid acute chemoresistance. Furthermore, ATRA shows reduced physicochemical 
stability, aqueous solubility and plasma half-life. Nanocarriers have emerged as promising strategies 
for delivering drugs to tumors. Therefore, this study aimed at developing an ATRA-based liposomal 
formulation with enhanced stability and therapeutic efficacy. 
ATRA-loaded liposomes (L-ATRA) were prepared by ethanol injection from egg phosphatidylcholine 
and cholesterol. Design of Experiments (DOE) was employed to study the influence of several 
formulation factors on the quality attributes of L-ATRA. 11 formulations were prepared according to a 
23 full factorial design, and characterized in terms of size, polydispersity, ATRA content and entrapment 
efficiency. An optimum liposomal formulation with desirable characteristics was evaluated in vitro 
regarding ATRA release. 
L-ATRA exhibited a mean size of 200-400 nm, and a narrow size distribution (polydispersity index < 
0.25). ATRA was successfully loaded into the liposomes with an efficiency of 70-80%. According to the 
DOE statistical analysis, L-ATRA attributes were mainly influenced by the concentrations of 
phospholipid and ATRA. The in vitro release study showed a maximum percentage of 72.5% ATRA 
released after 48h in a mixture of PBS pH 6.5 and ethanol 1:1 (v/v) at 37°C. 
Overall, this study reports the successful formulation and preparation of an ATRA-loaded liposomal 
formulation by DOE. L-ATRA could be a promising candidate for effective and safe delivery of ATRA in 
cancer patients. 
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